Skip to main content

Advertisement

SpringerLink
Log in

HOXB9 Expression Promoting Tumor Cell Proliferation and Angiogenesis Is Associated with Clinical Outcomes in Breast Cancer Patients

  • Breast Oncology
  • Published:
Annals of Surgical Oncology Aims and scope Submit manuscript

Abstract

Background

Studies have suggested that HOXB9 expression in breast cancer cells promotes cellular invasiveness, metastatic ability, and tumor neovascularization in the surrounding tissue in in vitro and in vivo assays. These findings imply that HOXB9 overexpression may alter tumor-specific cell fates and the tumor stromal microenvironment, contributing to breast cancer progression. The objective of this study was to analyze whether these results could be applied to clinical practice.

Methods

A total of 141 consecutive, invasive ductal carcinoma patients who underwent surgical treatment were examined. Immunohistochemical staining was performed to evaluate the expression of HOXB9, Ki-67, CD31, and CD34, and the association of tumor proliferation and angiogenesis with HOXB9 expression was analyzed.

Results

Of the 141 tumor specimens immunostained for HOXB9, 69 (48.9%) stained positive. Larger primary tumor size, hormone receptor negativity, HER2 positivity, higher nuclear grade, and number of pathologic nodal metastases were significant variables associated with HOXB9 expression. Notably, 12 (92.3%) of 13 triple-negative breast cancer cases showed HOXB9 expression. Disease-free survival and overall survival were significantly different between the HOXB9-positive and HOXB9-negative groups (hazard ratio 20.714, P = 0.001; and hazard ratio 9.206, P = 0.003, respectively). Multivariate analysis indicated that HOXB9 expression was the only independent prognostic factor for disease-free survival (hazard ratio 15.532, P = 0.009). HOXB9-positive tumors showed a significant increase in the number of vasculature and the Ki-67 ratio compared with HOXB9-negative tumors.

Conclusions

HOXB9 expression, which promotes tumor proliferation and angiogenesis, is a significant prognostic factor in breast cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55:74–108.

    Article  PubMed  Google Scholar 

  2. Goldhirsch A, Ingle JN, Gelber RD, Coates AS, Thurlimann B, Senn HJ. Thresholds for therapies: highlights of the St Gallen international expert consensus on the primary therapy of early breast cancer 2009. Ann Oncol. 2009;20:1319–29.

    Article  PubMed  CAS  Google Scholar 

  3. Abate-Shen C. Deregulated homeobox gene expression in cancer: cause or consequence? Nat Rev Cancer. 2002;2:777–85.

    Article  PubMed  CAS  Google Scholar 

  4. Hatzis P, van der Flier LG, van Driel MA, et al. Genome-wide pattern of TCF7L2/TCF4 chromatin occupancy in colorectal cancer cells. Mol Cell Biol. 2008;28:2732–44.

    Article  PubMed  CAS  Google Scholar 

  5. Calvo R, West J, Franklin W, et al. Altered HOX and WNT7A expression in human lung cancer. Proc Natl Acad Sci USA. 2000;97:12776–81.

    Article  PubMed  CAS  Google Scholar 

  6. Nguyen DX, Chiang AC, Zhang XH, et al. WNT/TCF signaling through LEF1 and HOXB9 mediates lung adenocarcinoma metastasis. Cell. 2009;138:51–62.

    Article  PubMed  CAS  Google Scholar 

  7. Hayashida T, Takahashi F, Chiba N, et al. HOXB9, a gene overexpressed in breast cancer, promotes tumorigenicity and lung metastasis. Proc Natl Acad Sci USA. 2010;107:1100–5.

    Article  PubMed  CAS  Google Scholar 

  8. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med. 1995;1:27–31.

    Article  PubMed  CAS  Google Scholar 

  9. Folkman J. Role of angiogenesis in tumor growth and metastasis. Semin Oncol. 2002;29(6 Suppl. 16):15–8.

    PubMed  CAS  Google Scholar 

  10. Linderholm BK, Hellborg H, Johansson U, et al. Significantly higher levels of vascular endothelial growth factor (VEGF) and shorter survival times for patients with primary operable triple-negative breast cancer. Ann Oncol. 2009;20:1639–46.

    Article  PubMed  CAS  Google Scholar 

  11. Allred DC, Harvey JM, Berardo M, Clark GM. Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol. 1998;11:155–68.

    PubMed  CAS  Google Scholar 

  12. Harvey JM, Clark GM, Osborne CK, Allred DC. Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol. 1999;17:1474–81.

    PubMed  CAS  Google Scholar 

  13. Nielsen TO, Hsu FD, Jensen K, et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res. 2004;10:5367–74.

    Article  PubMed  CAS  Google Scholar 

  14. al-Sader MH, Doyle E, Kay EW, et al. Proliferation indexes—a comparison between cutaneous basal and squamous cell carcinomas. J Clin Pathol. 1996;49:549–51.

    Article  PubMed  CAS  Google Scholar 

  15. Cattoretti G, Becker MH, Key G, et al. Monoclonal antibodies against recombinant parts of the Ki-67 antigen (MIB 1 and MIB 3) detect proliferating cells in microwave-processed formalin-fixed paraffin sections. J Pathol. 1992;168:357–63.

    Article  PubMed  CAS  Google Scholar 

  16. McCormick D, Chong H, Hobbs C, Datta C, Hall PA. Detection of the Ki-67 antigen in fixed and wax-embedded sections with the monoclonal antibody MIB1. Histopathology. 1993;22:355–60.

    Article  PubMed  CAS  Google Scholar 

  17. McCormick D, Yu C, Hobbs C, Hall PA. The relevance of antibody concentration to the immunohistological quantification of cell proliferation–associated antigens. Histopathology. 1993;22:543–7.

    Article  PubMed  CAS  Google Scholar 

  18. Bluff JE, Menakuru SR, Cross SS, et al. Angiogenesis is associated with the onset of hyperplasia in human ductal breast disease. Br J Cancer. 2009;101:666–72.

    Article  PubMed  CAS  Google Scholar 

  19. Davies G, Salter J, Hills M, Martin LA, Sacks N, Dowsett M. Correlation between cyclooxygenase-2 expression and angiogenesis in human breast cancer. Clin Cancer Res. 2003;9:2651–6.

    PubMed  CAS  Google Scholar 

  20. Goodman WA, Levine AD, Massari JV, Sugiyama H, McCormick TS, Cooper KD. IL-6 signaling in psoriasis prevents immune suppression by regulatory T cells. J Immunol. 2009;183:3170–6.

    Article  PubMed  CAS  Google Scholar 

  21. Zhou D, Cheng SQ, Ji HF, et al. Evaluation of protein pigment epithelium–derived factor (PEDF) and microvessel density (MVD) as prognostic indicators in breast cancer. J Cancer Res Clin Oncol. 2010;136:1719–27.

    Article  PubMed  CAS  Google Scholar 

  22. Bettencourt MC, Bauer JJ, Sesterhenn IA, Connelly RR, Moul JW. CD34 immunohistochemical assessment of angiogenesis as a prognostic marker for prostate cancer recurrence after radical prostatectomy. J Urol. 1998;160:459–65.

    Article  PubMed  CAS  Google Scholar 

  23. Vartanian RK, Weidner N. Correlation of intratumoral endothelial cell proliferation with microvessel density (tumor angiogenesis) and tumor cell proliferation in breast carcinoma. Am J Pathol. 1994;144:1188–94.

    PubMed  CAS  Google Scholar 

  24. Micalizzi DS, Christensen KL, Jedlicka P, et al. The Six1 homeoprotein induces human mammary carcinoma cells to undergo epithelial–mesenchymal transition and metastasis in mice through increasing TGF-beta signaling. J Clin Invest. 2009;119:2678–90.

    Article  PubMed  CAS  Google Scholar 

  25. Yu M, Smolen GA, Zhang J, et al. A developmentally regulated inducer of EMT, LBX1, contributes to breast cancer progression. Genes Dev. 2009;23:1737–42.

    Article  PubMed  CAS  Google Scholar 

  26. Sarrió D, Rodriguez-Pinilla SM, Hardisson D, Cano A, Moreno-Bueno G, Palacios J. Epithelial–mesenchymal transition in breast cancer relates to the basal-like phenotype. Cancer Res. 2008;68:989–97.

    Article  PubMed  Google Scholar 

  27. Ganapathy V, Ge R, Grazioli A, et al. Targeting the transforming growth factor-beta pathway inhibits human basal-like breast cancer metastasis. Mol Cancer. 2010;9:122.

    Article  PubMed  Google Scholar 

  28. Jain RK. Molecular regulation of vessel maturation. Nat Med. 2003;9:685–93.

    Article  PubMed  CAS  Google Scholar 

  29. Millanta F, Lazzeri G, Vannozzi I, Viacava P, Poli A. Correlation of vascular endothelial growth factor expression to overall survival in feline invasive mammary carcinomas. Vet Pathol. 2002;39:690–6.

    Article  PubMed  CAS  Google Scholar 

  30. Toi M, Kashitani J, Tominaga T. Tumor angiogenesis is an independent prognostic indicator in primary breast carcinoma. Int J Cancer. 1993;55:371–4.

    Article  PubMed  CAS  Google Scholar 

  31. Weidner N, Semple JP, Welch WR, Folkman J. Tumor angiogenesis and metastasis—correlation in invasive breast carcinoma. N Engl J Med. 1991;324:1–8.

    Article  PubMed  CAS  Google Scholar 

  32. Uzzan B, Nicolas P, Cucherat M, Perret GY. Microvessel density as a prognostic factor in women with breast cancer: a systematic review of the literature and meta-analysis. Cancer Res. 2004;64:2941–55.

    Article  PubMed  CAS  Google Scholar 

  33. Borg A, Tandon AK, Sigurdsson H, et al. HER-2/neu amplification predicts poor survival in node-positive breast cancer. Cancer Res. 1990;50:4332–7.

    PubMed  CAS  Google Scholar 

  34. Carter CL, Allen C, Henson DE. Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases. Cancer. 1989;63:181–7.

    Article  PubMed  CAS  Google Scholar 

  35. Fisher B, Bauer M, Wickerham DL, et al. Relation of number of positive axillary nodes to the prognosis of patients with primary breast cancer. An NSABP update. Cancer. 1983;52:1551–7.

    Article  PubMed  CAS  Google Scholar 

  36. Ragaz J, Jackson SM, Le N, et al. Adjuvant radiotherapy and chemotherapy in node-positive premenopausal women with breast cancer. N Engl J Med. 1997;337:956–62.

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgment

The authors thank Chisato Saito, Hiroshi Okazaki, and Kazuhiro Miyao for their technical support and helpful discussions. This research was supported by the Ministry of Education, Culture, Sports, Science and Technology Grants-in-Aid for Scientific Research [B] (21791260 and 23791499 to T.H.) and [C] (22591442 to H.J., 21591677 to M.T.), and a Grant-in-Aid from the Global Center of Excellence Program entitled “Education and Research Center for Stem Cell Medicine” (Keio University).

Author information

Authors and Affiliations

  1. Department of Surgery, Keio University School of Medicine, Tokyo, Japan

    Hirohito Seki MD, Tetsu Hayashida MD, PhD, Hiromitsu Jinno MD, PhD, Michio Sakata MD, Maiko Takahashi MD & Yuko Kitagawa MD, PhD, FACS

  2. Division of Diagnostic Pathology, Keio University School of Medicine, Tokyo, Japan

    Shigemichi Hirose MD, PhD & Makio Mukai MD, PhD

  3. Department of Surgery, Massachusetts General Hospital and Harvard Medical School, Charlestown, MA, USA

    Shyamala Maheswaran PhD

Authors
  1. Hirohito Seki MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Tetsu Hayashida MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Hiromitsu Jinno MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Shigemichi Hirose MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Michio Sakata MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Maiko Takahashi MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Shyamala Maheswaran PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Makio Mukai MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Yuko Kitagawa MD, PhD, FACS
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Tetsu Hayashida MD, PhD.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary material 1 (PDF 267 kb)

Rights and permissions

Reprints and permissions

About this article

Cite this article

Seki, H., Hayashida, T., Jinno, H. et al. HOXB9 Expression Promoting Tumor Cell Proliferation and Angiogenesis Is Associated with Clinical Outcomes in Breast Cancer Patients. Ann Surg Oncol 19, 1831–1840 (2012). https://doi.org/10.1245/s10434-012-2295-5

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1245/s10434-012-2295-5

Keywords

Search

Navigation